CD8A and neoplasm: The simulations demonstrated that Treg-modulating monotherapy modestly enhanced CD8+ T-cell activity and induced partial tumor cell killing, whereas the combination of Treg-targeted therapy and PD-1 blockade produced a synergistic enhancement of cytotoxic activity and tumor reduction.